Ser57
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.3
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Ser57  -  MCU (human)

Site Information
TVHQRIAsWQNLGAV   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 27259016

In vivo Characterization
Methods used to characterize site in vivo:
immunoassay ( 1 ) , immunoprecipitation ( 1 ) , mutation of modification site ( 1 ) , phospho-antibody ( 1 ) , western blotting ( 1 )
Disease tissue studied:
bone cancer ( 1 )
Relevant cell line - cell type - tissue:
E.coli (bacterial) ( 1 ) , HEK293T (epithelial) ( 1 ) , HeLa (cervical) ( 1 ) , U2OS (bone cell) ( 1 )

Upstream Regulation
Putative in vivo kinases:
AMPKA1 (human) ( 1 )
Kinases, in vitro:
AMPKA1 (human) ( 1 )
Treatments:
A-769662 ( 1 ) , DMSO ( 1 ) , metformin ( 1 ) , nocodazole ( 1 )

Downstream Regulation
Effects of modification on MCU:
activity, induced ( 1 ) , intracellular localization ( 1 )
Effects of modification on biological processes:
cell cycle regulation ( 1 )

References 

1

Zhao H, et al. (2019) AMPK-mediated activation of MCU stimulates mitochondrial Ca entry to promote mitotic progression. Nat Cell Biol 21, 476-486
30858581   Curated Info

Developed with grants from  NIH Logo and literature mining with Linguamatics  I2E Logo Creative Commons License PhosphoSite, created by Cell Signaling Technology is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported License.

©2003-2019 Cell Signaling Technology, Inc.